Imported cases of dengue fever in Russia during 2010–2013

Sergeeva EI*, Temovoi VA, Chausov EV, Berillo SA, Demina OK, Shikov AN, Plasunova IV, Kartashov MJu, Agafonov AP

State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Novosibirsk Region, 630559, Russia

ABSTRACT

Objective: To confirm dengue infection among Russian tourists returned from Southeast Asia and Mexico in 2010–2013 with clinical signs of infection. Methods: Blood and serum samples from patients were collected. NS1 antigen and human IgM/IgG antibodies to dengue virus were identified using commercial tests manufactured by “Standard Diagnostics, INC.”, Korea. ELISA test was used for the quantitative analyses of human IgM/IgG antibodies to dengue virus (“Orgenics Ltd.”, Israel). Viral RNA was detected using commercial real-time PCR tests manufactured by “Genome Diagnostics Pvt. Ltd.”, India and “Vector”, Russia. Genotypes of revealed dengue viruses were determined employing nucleotide sequencing and phylogenetic analysis of 5’–UTR of the viral genome. Results: A total of 98 collected blood samples were analyzed. Fifty samples were positive for at least one of four markers of dengue infection. IgM to dengue virus were revealed in 38 samples, in 25 samples IgM were combined with IgG. NS1 antigen was detected in 43 samples. 23 serum samples were positive for dengue virus RNA. The majority of samples (12 patients) from tourists returned from Thailand were positive for genotype 1 of dengue virus, 2nd and 4th genotype were identified each in 1 patient. Conclusions: Due to laboratory confirmed cases of imported dengue fever in Russia, the differential diagnosis of dengue is strictly recommended for tourists returning from endemic areas.

1. Introduction

Dengue fever is endemic in more than 100 countries in Africa, the Americas, Eastern Mediterranean, Southeast Asia and the Western Pacific. According to the WHO data, up to 100 million people are infected every year worldwide with dengue fever[1,2]. However, recent studies show that the total number of cases might range from 217 to 392 million. Asia countries account about 70% of this cases (India-33%), 16% happen in Africa, about 14% in the Americas (where more than half of infections occur in Brazil and Mexico)[3]. In Southeast Asia and Western Pacific Ocean about 1.8 billion people (more than 70% of total population) are at risk for dengue virus infection. Dengue fever epidemics are a major public health problem for India, China, Indonesia, Myanmar, Sri Lanka, Thailand and Timor–Leste while in urban and rural areas of these countries mosquito Aedes aegypti (Ae. aegypti) is breeding[4].

Russian Federation is not endemic for dengue fever and the cases of infection were not recorded until 2010[5], despite the fact that 40 species of mosquitoes of the genus Aedes (Ae.) reside in the country. This genus inhabit area that covers 5 regions of Federation and hatching of Ae. aegypti and Aedes albopictus Skuse is possible around the settlements of southern Russian (the coast of Black Sea, Caucasus). Mosquito of the genus Aedes become infectious in 8–12 days after blood-sucking. Their ability of being infectious continuous lifelong, ie. 1–3 months. However, the replication of the virus in mosquitoes doesn’t happen if the temperature is below 22 ºC, therefore the area of high virus spread is less than inhabitable area of dengue mosquitoes and limited to 42° north and 40° south latitude[6]. In view of permanently high level of dengue fever morbidity worldwide and habitat expansion of mosquitoes of the genus Aedes
due to global warming, the imported cases of dengue fever in non-endemic areas registered more often[7-9]. In recent years, the number of Russian citizens visiting the dengue-endemic countries rose exponentially, consequently the risk of the pathogen importation to the Russian Federation from abroad is dramatically increased.

The research seeks to prove the significance of dengue fever threat for such non-endemic territories like Russia. The purpose of the work was to confirm dengue infection among Russian tourists returned from Southeast and Mexico in 2010–2013 with clinical signs of infection.

2. Materials and methods

Blood and serum samples from patients who got ill within 21 days after returning from Thailand, Indonesia, Vietnam and Mexico were collected in hospital communicable diseases units in 15 regions of Russia. Considering involvement of humans in this research, all activities were undertaken under ethical clearance issued by the ethical committee of hospitals where patients were monitored. All patients gave an informed consent on investigations.

In order to identify dengue virus NS1 antigen and human IgM/IgG antibodies to dengue virus “SD BIOLINE Dengue NS1 Ag + Ab Combo Test” and “Dengue NS1Ag + Ab Combo” (“Standard Diagnostics, INC.”, Korea) tests were used according to the manufacturer’s instructions. For the quantitative analyses of human IgM/IgG antibodies to dengue virus “ImmunoComb® Dengue IgM/IgG Bispot” (“Orgenics Ltd.”, Israel) ELISA test was used. To determine primary dengue infection and reinfection in serum samples collected in febril phase IgM/IgG ratio was calculated. Acute patients with primary infection have a higher IgM/IgG ratio than found in secondary infections, when the index is over 1.78 the infection considered primary, less—secondary[10,11].

Viral RNA was extracted using “QIAamp Viral RNA Mini Extraction Kit” (“Qiagen”, Netherlands). Real–Time PCR was performed using “Gene–Sen’s DENGUE 1–4 Real Time PCR Kit” (“Genome Diagnostics Pvt. Ltd.”, India) and “Vector–PCR–RT–Dengue (1–4)–RG” (“Vector”, Russia) according to the manufacturer’s instructions.

In accordance with protocol for differential diagnosis of dengue fever approved by WHO all the samples were tested for markers of infections caused by Lassa, Machupo, Junin, Marburg, Ebola, Japanese and tick–born encephalitis, Chikungunya, West Nile viruses. More than 40 of the observed patients were treated in hospital communicable diseases unit, while the physical condition of 28 patients was evaluated as moderate complexity, and 14 patients had severe physical condition. All cases had favorable prognosis. From outpatient cards is known that all the infections were accompanied by typical signs of dengue fever: fever, arthralgia, myalgia, weakness,
The topology of the tree was reconstructed by Neighbor-Joining Phylogenetic analysis of the nucleotide sequences of 5′ untranslated region (1-285 bp) of genomes of prototype and clinical isolates of dengue virus.

Figure 1. Phylogenetic analysis of the nucleotide sequences of 5′–untranslated region (1–285 bp) of genomes of prototype and clinical isolates of dengue virus.

The topology of the tree was reconstructed by Neighbor–Joining method. The matrix of genetic distances was calculated using the Kimura two–parameter metric approach.

In 2011–2012 two strains of dengue virus 2 serotype were isolated: DENV–2–Novosibirsk–2011 and DENV–2–MX–Novosibirsk–2012. In 2013 two strains of dengue virus subtypes 1 and 4 – DENV–1–Novosibirsk–2013 and DENV–4–Novosibirsk–2013 were isolated. All strains were deposited to the State Collection of viral and rickettsiosis pathogens in the State Research Center of Virology and Biotechnology “VECTOR”.

4. Discussion

According to regional office of the WHO for South–East Asia, 9418 (7 lethal) cases of dengue fever were registered in Thailand from 1 January to 10 May 2011, while 16110 (20 lethal) cases were registered during the same period of the previous year. In total 80065 and 57948 cases of dengue fever were registered in Indonesia and Thailand in 2010, respectively[12].

The peak incidence of dengue fever in Indonesia is occurring in January–February, while in Thailand the majority of dengue fever cases are registered in July–September. It happens due to rainy period and development of favorable conditions for mosquitoes breeding[13]. In Europe the majority of imported dengue fever cases are registered among travelers returning from Southeast Asia, following by Latin America, India, the Caribbean and Africa[14]. Of the 50 patients, 46 patients with laboratory–confirmed dengue infection came from Thailand, 2–from Vietnam, 1–from Indonesia and 1–from Mexico.

Dengue fever presents with a wide spectrum of clinical manifestations, often infection has an unpredictable course and outcome[15]. The disease is characterized by rapid progression toward the development of serious medical complications which may be incompatible with life. Among the complications the most common are gastrointestinal bleeding, multisystem organ failure, disseminated intravascular coagulation, shock. Acute hepatic and renal failure, encephalopathy, cardiomyopathy are uncommon[15]. The clinical manifestation of the disease was the same as described in the literature.

The most efficient tests for dengue fever diagnosis were NS1 antigen and IgM antibodies to dengue virus detection. NS1 antigen of dengue virus was detected in 78% of patients, IgM antibodies to virus in 70%. Dengue virus RNA was detected in 20% of cases. Lack of dengue virus RNA in serum samples in PCR study can be explained by the fact of significant decrease of viral RNA titer in blood to the second week from the onset of the infection (mostly blood samples were collected on the 2nd week and later from the onset of the infection).

IgM titer during the re–infection caused by another subtype of dengue virus is significantly lower than during the first meeting with antigen[16]. This observation is an important
prognostic sign, while re-infection with the dengue virus is a risk factor for severe complications and death.[16–18]. The analysis showed that only 2 patients during the fibril period had the IgM/IgG ratio lower than 1.78, it can indicate re-infection with dengue virus. The course of the disease in these two patients was assessed as severe. The epidemiological investigation revealed that these patients have visited countries of Southeast Asia.

In conclusion, due to laboratory confirmed cases of imported dengue fever in Russia, the differential diagnosis of dengue is strictly recommended in tourists returning from endemic areas.

Conflict of interest statement

We declare that we have no conflict of interest.

References


